Advances in Biomarkers for Risk Stratification in Barrett's Esophagus

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Dysplasia currently is the primary biomarker used to risk stratify patients with Barrett's esophagus, but dysplasia has a number of considerable limitations in this regard. Thus, investigators over the years have explored innumerable alternative molecular biomarkers for risk stratification in Barrett's esophagus. This report focuses only on those biomarkers that appear most promising based on the availability of multiple published studies corroborating good results, and on the commercial availability of the test. These promising biomarkers include p53 immunostaining, TissueCypher, BarreGEN, and wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS3D).

Original languageEnglish (US)
Pages (from-to)105-115
Number of pages11
JournalGastrointestinal Endoscopy Clinics of North America
Issue number1
StatePublished - Jan 2021
Externally publishedYes


  • Dysplasia
  • Esophageal adenocarcinoma
  • Mutational load
  • Systems biology
  • p53

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Advances in Biomarkers for Risk Stratification in Barrett's Esophagus'. Together they form a unique fingerprint.

Cite this